
Opinion|Videos|August 19, 2024
Patient Access Advocacy for BTK Inhibitors
A panel of specialists discuss patient access advocacy for BTK inhibitors.
Advertisement
Video content above is prompted by the following:
- How do changes in patient out-of-pocket costs under the IRA influence treatment and sequencing decisions?
- What strategies can healthcare providers use to advocate for patient access to BTK inhibitors?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Major Bleeding Prevention, Treatment Requires Vigilance in Patients With ET
2
Trust and Transparency Key for Leveraging AI to Expand Access to Precision Oncology
3
Medicare Insulin Savings Model Cuts Costs, Boosts Access, Report Finds
4
Executive Order on Homelessness Includes Several Policy Shifts: Katherine Koh, MD, MSc
5